{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:28:26Z","timestamp":1770521306965,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"6932","license":[{"start":{"date-parts":[[1994,3,26]],"date-time":"1994-03-26T00:00:00Z","timestamp":764640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[1994,1,25]]},"published-print":{"date-parts":[[1994,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    : To determine the current practice in selected general practices for prescribing long term (&gt;6 months) treatment to suppress gastric acid secretion.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting<\/jats:bold>\n                    : Seven general practices in the Harrow area that always or usually refer to Northwick Park Hospital. Subjects--60 148 patients on lists of the general practices.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    : Identification of patients receiving long term treatment through repeat prescribing data, followed by a manual and computer survey of patients' notes for indications and investigations. Patient compliance and views on treatment were sought by a postal questionnaire.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measures<\/jats:bold>\n                    : Indications for treatment, treatment given, investigations undertaken before and during treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : 492 patients (0.82% of the population) were taking long term acid suppressing treatment. The most common diagnosis was duodenal ulcer disease (183 (37%) of all patients); oesophageal disease (118 (24%)) was also common. 93 patients (19%) were treated for abdominal pain where no diagnosis had been reached or who had only a diagnosis of gastritis on endoscopy. Ranitidine was prescribed in 394 (80%) patients. 298 (74%) patients found treatment helpful, but 108 (27%) had a poor understanding of their diagnosis. 317 patients (78%) took their drug as prescribed. 37 patients were also taking prescribed non-steroidal anti-inflammatory drugs and an additional 43 patients took regular aspirin or ibuprofen without prescription.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : Long term acid suppressing treatment is common, and a substantial number of patients are taking these drugs long term without a diagnosis having been reached. It is hoped that protocols for investigation and treatment will improve these figures. Patients need to be better informed about their disease and the possible adverse effects of taking non-steroidal antiinflammatory drugs in acid related upper gastrointestinal disease.\n                  <\/jats:p>","DOI":"10.1136\/bmj.308.6932.827","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:21:04Z","timestamp":1319743264000},"page":"827-830","source":"Crossref","is-referenced-by-count":73,"title":["Long term acid suppressing treatment in general practice"],"prefix":"10.1136","volume":"308","author":[{"given":"Stephen D","family":"Ryder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meron R","family":"Jacyna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Jonathon","family":"Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1994,3,26]]},"reference":[{"key":"2025122309563868000_308.6932.827.1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00004836-198606002-00006","article-title":"A multicenter study of ranitidine treatment of duodenal ulcers in the United States","volume":"8","author":"Hirschowitz","year":"1986","journal-title":"J Clin Gastroenterol"},{"key":"2025122309563868000_308.6932.827.2","first-page":"27","article-title":"The role of omeprazole in healing and prevention of reflux disease","volume":"39","author":"Klinkenberg-Knoll","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"2025122309563868000_308.6932.827.3","first-page":"9","article-title":"H(sub 2)-receptor antagonists","volume":"1","year":"1990","journal-title":"MeReC Bulletin"},{"key":"2025122309563868000_308.6932.827.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400160044009"},{"key":"2025122309563868000_308.6932.827.5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7326\/0003-4819-112-2-140","article-title":"Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy","volume":"112","author":"Mendelowitz","year":"1990","journal-title":"Ann Intern Med"},{"key":"2025122309563868000_308.6932.827.6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/AAC.36.1.163","article-title":"Role of metronidazole resistance in the therapy of Helicobacter pylori infection","volume":"36","author":"Rautelin","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2025122309563868000_308.6932.827.7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1128\/AAC.36.1.185","article-title":"Bacterial activity of antimicrobial agents against slowly growing Helicobacter pylori","volume":"36","author":"Millar","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2025122309563868000_308.6932.827.8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2036.1992.tb00051.x","article-title":"Review article: the treatment of Helicobacter pylori infection","volume":"6","author":"Heatley","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122309563868000_308.6932.827.9","first-page":"655","article-title":"Medical regimens in ulcer management","volume":"2","author":"Chiverton","year":"1988","journal-title":"Clin Gastroenterol Int Pract Res"},{"issue":"suppl 1","key":"2025122309563868000_308.6932.827.10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.1991.tb00747.x","article-title":"Maintenance therapy for peptic ulcer disease","volume":"5","author":"Wormsley","year":"1991","journal-title":"Aliment Pharmacol Therap"},{"key":"2025122309563868000_308.6932.827.11","first-page":"1242","article-title":"H(sub 2) antagonist and duodenal ulcer recurrence. Analysis of efficacy and comment on safety, costs and patient selection","volume":"82","author":"Freston","year":"1987","journal-title":"Am J Gastroenterol"},{"key":"2025122309563868000_308.6932.827.12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/milmed\/150.6.300","volume":"150","author":"Saultz","year":"1985","journal-title":"Milit Med"},{"key":"2025122309563868000_308.6932.827.13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198105213042108","article-title":"A survey of cimetidine prescribing","volume":"304","author":"Cocco","year":"1981","journal-title":"N Engl J Med"},{"key":"2025122309563868000_308.6932.827.14","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/7.1.43"},{"issue":"suppl 1","key":"2025122309563868000_308.6932.827.15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2036.1991.tb00756.x","article-title":"Helicobacter pylori: review of research findings","volume":"5","author":"Dooley","year":"1991","journal-title":"Aliment Pharmacol Therap"},{"key":"2025122309563868000_308.6932.827.16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bmj.2.5412.809","article-title":"Peptic ulcer: a profile","volume":"2","author":"Fry","year":"1984","journal-title":"BMJ"},{"issue":"suppl 310","key":"2025122309563868000_308.6932.827.17","first-page":"1","article-title":"Long term results of medical and surgical treatment for peptic ulcer","volume":"125","author":"Krause","year":"1963","journal-title":"Acta Chir Scand"},{"issue":"suppl 132","key":"2025122309563868000_308.6932.827.18","first-page":"12","article-title":"Case 2: The chronically recurring ulcer","volume":"22","author":"Walan","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"2025122309563868000_308.6932.827.19","first-page":"1750","article-title":"Uncharacteristic dyspepsia in general practice: a controlled trial with aluminium aminoacetate and magnesium hydroxide","volume":"142","author":"Norrelund","year":"1980","journal-title":"Ugeskr Laeger"},{"key":"2025122309563868000_308.6932.827.20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0016-5085(86)90451-8","article-title":"Randomized, double blind, placebo controlled cross-over trial of cimetidine and pirenzepine in non-ulcer dyspepsia","volume":"91","author":"Talley","year":"1986","journal-title":"Gastroenterology"},{"key":"2025122309563868000_308.6932.827.21","doi-asserted-by":"publisher","DOI":"10.3109\/00365528809093874"},{"key":"2025122309563868000_308.6932.827.22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/00365528809093840","article-title":"Treatment with cimetidine, antacid or placebo in patients with dyspepsia of unknown origin","volume":"23","author":"Gotthard","year":"1988","journal-title":"Scand J Gastroenterol"},{"key":"2025122309563868000_308.6932.827.23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.1780280613","article-title":"Utilization of non-steroidal anti-inflammatory drugs","volume":"28","author":"Baum","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2025122309563868000_308.6932.827.24","first-page":"462","article-title":"Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo controlled trial","volume":"i","author":"Graham","year":"1986","journal-title":"Lancet"},{"key":"2025122309563868000_308.6932.827.25","first-page":"633","article-title":"A double blind, placebo controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms","volume":"84","author":"Lanza","year":"1989","journal-title":"Am J Gastroenterol"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.308.6932.827","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.308.6932.827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:56:46Z","timestamp":1766512606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.308.6932.827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,3,26]]},"references-count":25,"journal-issue":{"issue":"6932","published-online":{"date-parts":[[1994,3,26]]},"published-print":{"date-parts":[[1994,3,26]]}},"alternative-id":["10.1136\/bmj.308.6932.827"],"URL":"https:\/\/doi.org\/10.1136\/bmj.308.6932.827","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,3,26]]}}}